This article is cited in
12 papers
CHEMISTRY AND MATERIAL SCIENCE
Synthesis of GdFeO$_{3}$ nanoparticles via low-temperature reverse co-precipitation: the effect of strong agglomeration on the magnetic behavior
Ya. Albadiab,
K. D. Martinsonc,
A. V. Shvidchenkoc,
I. V. Buryanenkod,
V. G. Semenove,
V. I. Popkovc a Saint Petersburg State Institute of Technology, St. Petersburg, 190013, Russia
b Al-Baath University, Homs, 77, Syria
c Ioffe Institute, St. Petersburg, 194021, Russia
d Peter the Great St. Petersburg Polytechnic University, St. Petersburg, 195251, Russia
e Saint Petersburg State University, Petergof, St. Petersburg, 198504, Russia
Abstract:
Gadolinium orthoferrite (GdFeO
$_{3}$) seems to have potential as a dual-modal contrast agent for magnetic resonance imaging (MRI), thus its preparation in the form of ultrafine superparamagnetic nanoparticles is currently of great interest. In this work, nanocrystalline GdFeO
$_{3}$ was successfully synthesized by the heat treatment (750
$^{\circ}$C, 4 h) of gadolinium and iron(III) hydroxides reversely co-precipitated at low temperature (0
$^{\circ}$C). Initial and resulting powders were analyzed by EDX, SEM, PXRD, Mössbauer spectroscopy, vibration magnetometry, etc. Gadolinium orthoferrite was formed as isometric nanocrystals with an average size of 23
$\pm$3 nm, which were strongly agglomerated into clusters of about 200 nm in diameter. It was shown that the individual GdFeO
$_{3}$ nanocrystals are superparamagnetic, but in the cluster form, they exhibit a collective weak ferromagnetic behavior. After ultrasonic-assisted disintegration of GdFeO
$_{3}$ to a colloidal solution form, these clusters remained stable due to their strong agglomeration and low zeta potential value of 1 mV. Thus, it is concluded that the further use of the synthesized GdFeO
$_{3}$ nanoparticles as a basis of MRI contrast agents will be possible only after the suppression of their clustering.
Keywords:
gadolinium orthoferrite, nanoparticles, colloidal solutions, magnetic resonance imaging, contrast agents.
PACS:
81.20.Fw, 61.46.+w,
75.20.-g Received: 03.04.2020
Language: English
DOI:
10.17586/2220-8054-2020-11-2-252-259